Restore Medical, a leader in interventional cardiology innovations, has achieved a significant milestone with the U.S. Food and Drug Administration’s (FDA) Breakthrough Device Designation for its pioneering ContraBand device. This designation underscores the potential of ContraBand to transform the treatment landscape for patients suffering from heart failure with reduced ejection fraction (HFrEF), who have not […]
In a significant development for cardiovascular disease treatment, Cardurion Pharmaceuticals, Inc., a clinical-stage biotechnology company, has presented positive results from its Phase 2 proof-of-concept clinical trial, CARDINAL-HF. This trial tested CRD-740, a phosphodiesterase-9 (PDE9) inhibitor, showcasing its potential to become a new standard of care in heart failure therapy. These findings were revealed at the […]
China’s National Medical Products Administration (NMPA) has approved AstraZeneca’s Forxiga (dapagliflozin) for diminishing the risk of cardiovascular fatalities and hospitalizations in adults diagnosed with symptomatic chronic heart failure (HF). This follows an earlier authorization for patients suffering from heart failure with reduced ejection fraction (HFrEF). Now, Forxiga’s capabilities extend to all adults with symptomatic chronic […]
Hyloris Pharmaceuticals has acquired the global rights from Australia-based Baker Heart and Diabetes Institute (Baker Institute) to CRD-102, a clinical-stage, extended-release Milrinone capsule. CRD-102 is being developed for late-stage heart failure (HF) patients who have an implanted left ventricular assist device (LVAD1) and have developed right HF. According to Hyloris Pharmaceuticals, CRD-102 is the second […]
AstraZeneca has announced that its drug, Forxiga (dapagliflozin), has received approval from the Chinese National Medical Products Administration (NMPA) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) and reduced ejection fraction (HFrEF). This marks a significant step forward in the treatment options available […]
Swiss pharmaceutical giant Novartis has announced encouraging results from the TRANSITION phase 4 clinical trial, affirming that Entresto (sacubitril/valsartan) can be safely initiated early in a broad range of patients with heart failure with reduced ejection fraction (HFrEF), shortly after stabilization from an acute heart failure episode. This groundbreaking study underlines the effectiveness of Entresto […]
